Matthew Earnest, MD
Interventional Cardiology · Merriam, KSNPI 1730246992
Payments from drug & device makers
What this record shows
This record is dominated by consulting fees: $13,994 of the $22,224 with a category attached, or 63.0%. 36 manufacturers reported payments, led by Abbott at 53.0% of the total. Reporting peaked in 2019 at $11,057 and has fallen 96.5% since, to $384 in 2025.
Across 285 payments — averaging $77.98 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Abbott$12K
- Amgen$7K
- Medtronic$877
- Boston Scientific$671
- Pfizer$258
- Shockwave Medical, Inc$225
- plus $2K from 30 others
Across 9 payments — averaging $8695.11 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Abbott$78K
What the payments were for
- Consulting fees$13,99463%
- Travel & lodging$1,1265%
- Food & beverage$7,02532%
- Education$790%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Abbott | 67 | $11,774 |
| Amgen | 28 | $6,516 |
| Medtronic(2 entities) | 29 | $877 |
| Boston Scientific | 36 | $671 |
| Pfizer | 17 | $258 |
| Shockwave Medical, Inc | 1 | $225 |
| Novo Nordisk | 9 | $185 |
| Novartis | 11 | $177 |
| Johnson & Johnson | 11 | $170 |
| Abiomed | 7 | $165 |
| AstraZeneca(2 entities) | 9 | $154 |
| Merck | 8 | $135 |
| Bayer | 7 | $132 |
| Alnylam Pharmaceuticals Inc. | 5 | $90 |
| E.r. Squibb & Sons, L.L.C. | 5 | $78 |
| Edwards Lifesciences | 2 | $65 |
| Daiichi Sankyo Inc. | 3 | $59 |
| Sanofi-aventis U.S. LLC | 3 | $48 |
| Kiniksa Pharmaceuticals, Ltd. | 2 | $42 |
| Kiniksa Pharmaceuticals International, PLC | 2 | $39 |
| Atricure, Inc. | 2 | $37 |
| Lantheus Medical Imaging, Inc. | 2 | $34 |
| Lexicon Pharmaceuticals, Inc. | 2 | $33 |
| Actelion Pharmaceuticals US, Inc. | 2 | $32 |
| Amarin Pharma, Inc. | 2 | $32 |
| ZOLL Services LLC (a/k/a ZOLL Lifecor Corp) | 2 | $26 |
| Irhythm Technologies, Inc. | 1 | $23 |
| Biotronik Inc. | 1 | $21 |
| Boehringer Ingelheim | 1 | $19 |
| GE HealthCare | 1 | $18 |
| Baxter Healthcare | 1 | $17 |
| Teleflex LLC | 1 | $17 |
| Chiesi USA, Inc. | 1 | $16 |
| Amryt Pharma Holdings Ltd | 1 | $14 |
| W. L. Gore & Associates, Inc. | 1 | $12 |
| Preventice Services, LLC | 2 | $11 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- Xience V coronary stent system$9,190
- Repatha$5,677
- Optis Coronary Imaging System$444
- AMPLATZER Occluders$288
- Shockwave IVL System with the Shockwave C2 Coronary IVL Catheter$225
- MitraClip$171
- Xience Sierra Coronary Stent System$150
- XIENCE SIERRA$150
- CardioMEMS HF System$143
- Impella$134
- Resolute$129
- SYMPLICITY G3$125
- Watchman$121
- THORATEC HEARTMATE 3 LVAS IMPLANT KIT$110
How this compares
$22,224 in reported general payments places this provider in the 75th percentile of 55 interventional cardiology providers in Kansas.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| EliquisApixaban | 138 | $165,004 |
| Repatha SureclickEvolocumab | 45 | $39,298 |
| JardianceEmpagliflozin | 20 | $33,251 |
| BrilintaTicagrelor | 38 | $28,651 |
| EntrestoSacubitril/Valsartan | 16 | $24,918 |
| XareltoRivaroxaban | 12 | $15,232 |
| Praluent PenAlirocumab | 11 | $11,759 |
| BenicarOlmesartan Medoxomil | 13 | $6,167 |
| Metoprolol Succinate | 427 | $4,711 |
| Rosuvastatin Calcium | 320 | $3,967 |
| Atorvastatin Calcium | 298 | $2,794 |
| Ranolazine ErRanolazine | 21 | $2,752 |
| Diltiazem 24hr Er (Cd)Diltiazem Hcl | 32 | $1,814 |
| Losartan Potassium | 189 | $1,469 |
| Isosorbide Mononitrate ErIsosorbide Mononitrate | 46 | $1,215 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| PfizerEliquis | $258 | $165,004138 claims |
| Boehringer IngelheimJardiance | $19 | $33,25120 claims |
| AstraZenecaBrilinta | $154 | $28,65138 claims |
| NovartisEntresto | $177 | $24,91816 claims |
| Johnson & JohnsonXarelto | $170 | $15,23212 claims |
| Daiichi Sankyo Inc.Benicar | $59 | $6,16713 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 75th percentile of 55 interventional cardiology providers in Kansas.
Other interventional cardiology in Merriam
- Ammar HabibMerriam$11K
- Anthony AlbrachtMerriam$7K
- Jason D'souzaMerriam$6K
- Anthony SpaedyKansas City$385K
- Prasad GunasekaranKansas City$76K
- Maheedhar GedelaWichita$54K
- Kamal GuptaKansas City$46K
- Priyantha RanaweeraManhattan$41K
- Mark WileyKansas City$39K
- Ahmed SoukaTopeka$37K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.